NRx Pharmaceuticals, Inc. (NRXP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, is gearing up to disclose its financial achievements for the fourth quarter and the entire year ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE ...

NRx Pharmaceuticals (NRXP)’ wholly-owned subsidiary Hope Therapeutics signed a Stock Purchase Agreement with Smith & Sauer as the first step in a $27.0M financing to fund the planned acquisition ...

NRX invested $27 million in its subsidiary HOPE therapeutics to fund a nationwide rollup of Interventional Psychiatry Clinics. The agreement includes an immediate $2 million investment with a ...

HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital ...

NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute. The stock rose Thursday to $2.92, reaching a six-month high.

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics. NRX shares are trading higher on Thursday after the company announced a ...

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a Delaware-based pharmaceutical company with a market capitalization of $61.63 million, announced the immediate resignation of Janet Rehnquist from its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...